Prevention and Treatment of RSV Bronchiolitis and Wheezing
Author Information
Author(s): Kimpen Jan LL
Primary Institution: Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
Hypothesis
Does treatment for RSV bronchiolitis affect long-term respiratory outcomes?
Conclusion
RSV-IGIV and palivizumab are effective for preventing RSV LRTI in high-risk children, but their long-term effects on asthma and wheezing are unclear.
Supporting Evidence
- RSV is the leading cause of hospitalization for respiratory illness in young children.
- 47% of infants hospitalized for RSV developed recurrent wheezing within a year.
- Ribavirin therapy shows no significant long-term benefits for respiratory outcomes.
- Palivizumab significantly reduces RSV-related hospitalizations in high-risk infants.
Takeaway
RSV can make kids very sick, and while some treatments help in the short term, we still don't know how to stop them from wheezing later.
Methodology
The study reviews various treatments and their effects on RSV bronchiolitis and subsequent wheezing.
Potential Biases
Some studies had methodological issues and subjective endpoints.
Limitations
The long-term effects of treatments on asthma and wheezing are not fully understood.
Participant Demographics
Infants and young children, particularly those at high risk for severe RSV infection.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website